STOCK TITAN

Fulcrum Therapeutics (FULC) director receives 32,000 stock options at $3.66 strike

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
4

Rhea-AI Filing Summary

Fulcrum Therapeutics director Sonja Banks received a new stock option grant. The award covers 32,000 shares of common stock at an exercise price of $3.66 per share and expires on June 29, 2036. All shares are scheduled to vest on the first anniversary of the June 30, 2026 grant date, or earlier immediately before the first annual stockholder meeting after the grant date, subject to continued service.

Positive

  • None.

Negative

  • None.
Insider Banks Sonja
Role null
Type Security Shares Price Value
Grant/Award Stock Option (right to buy) 32,000 $0.00 --
Holdings After Transaction: Stock Option (right to buy) — 32,000 shares (Direct, null)
Footnotes (1)
  1. [object Object]
Option grant size 32,000 options Director grant on June 30, 2026
Exercise price $3.66 per share Stock option strike price
Expiration date June 29, 2036 Option term end date
Post-grant derivative holdings 32,000 options Total options following transaction
Stock Option (right to buy) financial
"security_title: Stock Option (right to buy)"
exercise price financial
"conversion_or_exercise_price: 3.6600"
The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.
vesting financial
"is scheduled to vest with respect to all shares on the first anniversary"
Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.
expiration date financial
"expiration_date: 2036-06-29T00:00:00.000Z"
The expiration date is the deadline after which a financial contract, such as an option or a futures agreement, is no longer valid or can be exercised. It matters to investors because it determines the timeframe during which they can take action or benefit from the contract, similar to how a coupon or a food item has a limited period of usefulness. Once the expiration date passes, the contract loses its value or ability to be used.
See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Learn about SEC filing dates
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Banks Sonja

(Last)(First)(Middle)
C/O FULCRUM THERAPEUTICS, INC.
26 LANDSDOWNE STREET

(Street)
CAMBRIDGE MASSACHUSETTS 02139

(City)(State)(Zip)

UNITED STATES

(Country)
2. Issuer Name and Ticker or Trading Symbol
Fulcrum Therapeutics, Inc. [ FULC ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
XDirector10% Owner
Officer (give title below)Other (specify below)
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
06/30/2026
6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Stock Option (right to buy)$3.6606/30/2026A32,000 (1)06/29/2036Common Stock32,000$0.0032,000D
Explanation of Responses:
1. This option was granted on June 30, 2026 and is scheduled to vest with respect to all shares on the first anniversary of the grant date or, if earlier, immediately prior to the first annual meeting of stockholders occurring after the grant date, subject to continued service.
/s/ Greg Tourangeau, as attorney-in-fact for Sonja Banks07/02/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What did Fulcrum Therapeutics (FULC) director Sonja Banks report on this Form 4?

Director Sonja Banks reported receiving a stock option grant for 32,000 shares of Fulcrum Therapeutics common stock. The options were granted as compensation and are not an open-market purchase or sale of existing shares.

What is the exercise price and expiration date of Sonja Banks’ Fulcrum Therapeutics options?

The stock options have an exercise price of $3.66 per share and expire on June 29, 2036. This means she can buy up to 32,000 shares at $3.66 any time before that expiration, once vested.

How and when do Sonja Banks’ Fulcrum Therapeutics options vest?

All 32,000 options are scheduled to vest on the first anniversary of the June 30, 2026 grant date. Vesting can also occur earlier, immediately before the first annual stockholder meeting after the grant date, if that happens sooner, subject to continued service.

Did Sonja Banks buy or sell any Fulcrum Therapeutics shares in the market?

No market buy or sell occurred in this filing. The Form 4 reports a grant of stock options as compensation, not an open-market transaction, and no common shares were reported as bought or sold.

How many Fulcrum Therapeutics options does Sonja Banks hold after this grant?

After this grant, Sonja Banks holds 32,000 stock options according to the Form 4. These options give her the right to acquire up to 32,000 shares of common stock at $3.66 per share, subject to vesting.